NLRP3

NLRP3

A gene located on chromosome 1q44 that encodes a pyrin-like protein that interacts with the apoptosis-associated speck-like protein PYCARD/ASC. NLRP3 has a caspase recruitment domain, and belongs to the NALP3 inflammasome complex; it plays a role in regulating inflammation and apoptosis.
 
Molecular pathology
NLRP3 mutations are associated with chronic infantile neurological cutaneous and articular (CINCA) syndrome, familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome and neonatal-onset multisystem inflammatory disease (NOMID).
References in periodicals archive ?
Colchicine suppresses a multi-protein complex called NLRP3, which triggers the inflammation seen in obesity.
IFM Tre, a subsidiary of IFM Therapeutics, is a biopharmaceutical company developing a suite of small-molecule antagonists targeting inappropriate inflammatory responses of the innate immune system through the NLRP3 pathway, which is believed to underlie a variety of serious diseases.
Asimismo, se ha descrito que el virus de la inmunodeficiencia humana (VIH-1) tiene la capacidad de inducir la activacion del inflamasoma NLRP3 y una mayor produccion de IL-1[beta] (5).
Inflazome is developing orally available drugs to address clinical unmet needs in inflammatory diseases by targeting the NLRP3 inflammasome, which is now understood to drive many chronic and acute inflammatory conditions.
Many times, these disorders are associated with mutations in a specific gene-MEFV with familial Mediterranean fever (FMF), NLRP3 with Muckle-Wells syndrome (MWS), TNFRSF1A with tumor necrosis factor (TNF)-associated periodic syndrome (TRAPS), MVK with hyperimmunoglobulinemia D with periodic fever syndrome (HIDS), and LPIN2 with Majeed syndrome (1).
Global Banking News-November 28, 2018-Genentech to acquire preclinical portfolio of NLRP3 inhibitors from Jecure Therapeutics
Background: The nucleotide-binding and oligomerization domain-like receptor protein 3 (NLRP3) inflammasome composed of NLRP3, apoptosis-associated speck-like protein containing CARD (ASC), and caspase-1 is engaged in the inflammatory response of many kidney diseases and can be activated by purinergic 2X7 receptor (P2X7R).
"We found a key immune system target, called the NLRP3 inflammasome, lights up in Parkinson's patients, with signals found in the brain and even in the blood," Woodruff said.
Abstracts accepted for oral presentations included: "Multicenter, double-blind, randomized trial of emricasan in subjects post liver transplantation with recurrent hepatitis C virus and liver fibrosis or cirrhosis despite achieving sustained virologic response and "Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis."and abstracts accepted for posters included: "Molecular mechanisms underlying the effects of emricasan in portal hypertension and chronic liver disease: the hepato-sinusoidal cross-talk matters." Abstract #25 is an AASLD Foundation Abstract Award Recipient and was accepted for presentation in the Presidential Plenary Session on Translational Science and Genomics
Recently, the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome complex (including NOD-like receptor NLRP3, the adaptor molecule apoptosis-associated speck-like protein containing a caspase-recruitment domain, and the effector molecule procaspase-1) play a critical role in the pathogenesis of neuropathic pain (2, 5).
These current pathogenic concepts suggest new targets for therapy, including FoxO1, mTORC1, TLR2, the NLRP3 inflammasome, caspase-l, and IL-l-beta.
Uric acid was shown to induce NLRP3 inflammasome (also known as NRLP3, cryoprin and NALP3).